GILEAD SCIENCES, INC. is 8.3x more valuable than Moderna, Inc. by market capitalization ($151.05 B vs $18.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GILD | MRNA |
|---|---|---|
| Market cap | $151.05 B | $18.25 B |
| US-listed rank | #99 | #650 |
| Revenue (latest FY) | $29.44B | $1.94B |
| Net income (latest FY) | $8.51B | -$2.82B |
| Net margin | 28.9% | -145.2% |
| P/E (trailing FY) | 17.7 | - |
| SEC filings | 981 | 1,447 |
GILEAD SCIENCES, INC. is 8.3x more valuable than Moderna, Inc. by market capitalization ($151.05 B vs $18.25 B).
In their latest fiscal years, GILEAD SCIENCES, INC. reported $29.44B in revenue while Moderna, Inc. reported $1.94B.
Full pages: GILEAD SCIENCES, INC. and Moderna, Inc., or browse the full rankings.